

Optiscan Imaging Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Optiscan Imaging Limited
ABN:	81 077 771 987
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

2. Results for announcement to the market

Revenues from ordinary activities	down	-17.6%	to	\$ 951,948
Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited	up	4.1%	to	(6,311,952)
Loss for the year attributable to the owners of Optiscan Imaging Limited	up	4.1%	to	(6,311,952)

Dividends

There were no dividends paid or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$6,311,952 (30 June 2024: \$6,060,496).

Financial performance

During the financial year ending 30 June 2025 (FY25), the consolidated entity generated ordinary revenue of \$951,948 from sales, system rentals and the provision of services, compared to \$1,155,604 in the previous corresponding period. The 17.6% decrease in sales revenue was mainly due to lower orders from Carl Zeiss Meditec (CZM).

Other income generated for the financial year was \$3,106,879 (2024: \$2,378,064). The Company recorded research and development incentive income of \$2,410,376 (2024: \$994,658), an increase by 142% mainly due to the successful Advance and Overseas Finding that enables the Company to receive R&D tax incentive on overseas R&D cost. With multiple The gastrointestinal flexible endomicroscope project associated with the CRC-P grant also progressed, resulting in grant payments received of \$361,907 (2024: \$835,761).

Further investment in commercial and R&D activity for the financial period increased total expenses for FY25 to \$10,350,445 (2024: \$9,594,164). With higher investment in R&D over the year to achieve production-ready medical devices for regulatory submissions, the Company has been able to advance multiple R&D projects and also revealed two ground-breaking new microscopic medical imaging devices - InForm™ for pathology, and InSpecta™ for veterinary medicine. There was also increased business activities through strategic conference engagement, commercial initiatives, and adding capabilities to the team to deliver on the strategy that will advance clinical validation and commercial readiness.

The net operating cash outflow for FY25 was \$6,212,032 compared to \$5,744,450 for the previous financial year. This higher cash outflow is due to increased R&D and commercial activities as outlined above.

For personal use only

Optiscan Imaging Limited
Appendix 4E
Preliminary final report

Financial position

The net assets decreased by \$6,155,477 to \$7,712,014 at 30 June 2025 (30 June 2024: \$13,867,491). The working capital position of the consolidated entity as at 30 June 2025 resulted in an excess of current assets over current liabilities of \$7,354,694 (30 June 2024: \$13,311,323).

The decrease in net asset position was due to cash used over the course of the year for R&D and commercial activities.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>0.92</u>	<u>1.65</u>

The net tangible assets per ordinary security has been calculated excluding the Right-of-use asset amount and Intangibles.

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid or declared during the current financial period.

Previous period

There were no dividends paid or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

For personal use only

Optiscan Imaging Limited
Appendix 4E
Preliminary final report

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):


The financial statements have been audited and an unmodified opinion has been issued.

11. Attachments

Details of attachments (if any):

See the Optiscan Imaging Limited Annual Report for the period ended 30 June 2025 for further information.

12. Signed

Signed  _____

Date: 29 August 2025

Robert Cooke
Non-executive Chairman

For personal use only